Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Polymer therapeutics with a coiled coil motif targeted against murine bcl1 leukemia.

Pola R, Laga R, Ulbrich K, Sieglová I, Král V, Fábry M, Kabešová M, Kovář M, Pechar M.

Biomacromolecules. 2013 Mar 11;14(3):881-9. doi: 10.1021/bm3019592. Epub 2013 Feb 14.

PMID:
23373696
2.
3.

HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.

Kovár M, Mrkvan T, Strohalm J, Etrych T, Ulbrich K, Stastný M, Ríhová B.

J Control Release. 2003 Oct 30;92(3):315-30.

PMID:
14568412
4.

HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.

Etrych T, Strohalm J, Kovár L, Kabesová M, Ríhová B, Ulbrich K.

J Control Release. 2009 Nov 16;140(1):18-26. doi: 10.1016/j.jconrel.2009.07.011. Epub 2009 Jul 24.

PMID:
19632282
5.

Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.

Nakamura H, Koziolová E, Chytil P, Tsukigawa K, Fang J, Haratake M, Ulbrich K, Etrych T, Maeda H.

Mol Pharm. 2016 Dec 5;13(12):4106-4115. Epub 2016 Nov 21.

PMID:
27934482
6.

The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.

Tomalova B, Sirova M, Rossmann P, Pola R, Strohalm J, Chytil P, Cerny V, Tomala J, Kabesova M, Rihova B, Ulbrich K, Etrych T, Kovar M.

J Control Release. 2016 Feb 10;223:1-10. doi: 10.1016/j.jconrel.2015.12.023. Epub 2015 Dec 18.

PMID:
26708020
7.
8.

Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.

Ríhová B, Strohalm J, Hovorka O, Subr V, Etrych T, Chytil P, Pola R, Plocová D, Boucek J, Ulbrich K.

J Control Release. 2008 Apr 21;127(2):110-20. doi: 10.1016/j.jconrel.2008.01.003. Epub 2008 Jan 16.

PMID:
18325618
9.

Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes.

Ríhová B, Etrych T, Pechar M, Jelínková M, Stastný M, Hovorka O, Kovár M, Ulbrich K.

J Control Release. 2001 Jul 6;74(1-3):225-32.

PMID:
11489498
10.

Synthesis of poly[N-(2-hydroxypropyl)methacrylamide] conjugates of inhibitors of the ABC transporter that overcome multidrug resistance in doxorubicin-resistant P388 cells in vitro.

Subr V, Sivák L, Koziolová E, Braunová A, Pechar M, Strohalm J, Kabešová M, Ríhová B, Ulbrich K, Kovář M.

Biomacromolecules. 2014 Aug 11;15(8):3030-43. doi: 10.1021/bm500649q. Epub 2014 Jul 10.

PMID:
24978588
11.

Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.

Chytil P, Etrych T, Konák C, Sírová M, Mrkvan T, Ríhová B, Ulbrich K.

J Control Release. 2006 Sep 28;115(1):26-36. Epub 2006 Jun 30.

PMID:
16899320
12.

In vitro and in vivo effect of HPMA copolymer-bound doxorubicin targeted to transferrin receptor of B-cell lymphoma 38C13.

Kovár M, Strohalm J, Ulbrich K, Ríhová B.

J Drug Target. 2002 Feb;10(1):23-30.

PMID:
11996083
13.

Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.

Etrych T, Chytil P, Mrkvan T, Sírová M, Ríhová B, Ulbrich K.

J Control Release. 2008 Dec 18;132(3):184-92. doi: 10.1016/j.jconrel.2008.04.017. Epub 2008 Apr 29.

PMID:
18534705
14.

Polymer Cancerostatics Targeted with an Antibody Fragment Bound via a Coiled Coil Motif: In Vivo Therapeutic Efficacy against Murine BCL1 Leukemia.

Pechar M, Pola R, Janoušková O, Sieglová I, Král V, Fábry M, Tomalová B, Kovář M.

Macromol Biosci. 2018 Jan;18(1). doi: 10.1002/mabi.201700173. Epub 2017 Sep 15.

PMID:
28921867
15.

Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy.

Etrych T, Kovář L, Strohalm J, Chytil P, Ríhová B, Ulbrich K.

J Control Release. 2011 Sep 25;154(3):241-8. doi: 10.1016/j.jconrel.2011.06.015. Epub 2011 Jun 15.

PMID:
21699933
16.

Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic.

Duncan R, Gac-Breton S, Keane R, Musila R, Sat YN, Satchi R, Searle F.

J Control Release. 2001 Jul 6;74(1-3):135-46.

PMID:
11489490
17.

New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting.

Chytil P, Etrych T, Konák C, Sírová M, Mrkvan T, Boucek J, Ríhová B, Ulbrich K.

J Control Release. 2008 Apr 21;127(2):121-30. doi: 10.1016/j.jconrel.2008.01.007. Epub 2008 Jan 30.

PMID:
18304673
18.

Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl)methacrylamide copolymers through an amide or hydrazone bond.

Ríhová B, Etrych T, Sírová M, Kovár L, Hovorka O, Kovár M, Benda A, Ulbrich K.

Mol Pharm. 2010 Aug 2;7(4):1027-40. doi: 10.1021/mp100121g.

PMID:
20524698
19.
20.

Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.

Etrych T, Subr V, Laga R, Ríhová B, Ulbrich K.

Eur J Pharm Sci. 2014 Jul 16;58:1-12. doi: 10.1016/j.ejps.2014.02.016. Epub 2014 Mar 13.

PMID:
24632485

Supplemental Content

Support Center